NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT01822509 2021-06-24Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell TransplantNational Cancer Institute (NCI)Phase 1 Completed71 enrolled
NCT00732186 2016-02-17Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid LeukemiaBristol-Myers SquibbPhase 1 Withdrawn
NCT00060372 2013-03-27Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive CancerNational Cancer Institute (NCI)Phase 1 Completed21 enrolled